Radiopharmacokinetic and dosimetric parameters of ¹⁸⁸Re-lanreotide in athymic mice with induced human cancer tumorsMOLINA-TRINIDAD, Eva M; ARTEAGA DE MURPHY, Consuelo; FERRO-FLORES, Guillermina et al.International journal of pharmaceutics. 2006, Vol 310, Num 1-2, pp 125-130, issn 0378-5173, 6 p.Article

Effet antitumoral des analogues de la somatostatine dans les tumeurs neuroendocrines digestives = Antiproliferative effect of somatostatin analogs in neuroendocrine tumorsDE MESTIER, Louis; HENTIC, Olivia; BRIXI, Hedia et al.Hépato-gastro & oncologie digestive. 2014, Vol 21, Num 10, pp 835-844, issn 2115-3310, 10 p.Article

Influence du lanréotide sur la concentration sérique de prolactine chez les patients atteints de tumeurs somato-lactotropes = Effect of lanreotide on prolactin level in patients with pituitary mixed tumorsWASKO, R; SAWICKA, J; STACHOWIAK, C et al.Annales d'endocrinologie. 2002, Vol 63, Num 6, pp 532-535, issn 0003-4266, 4 p., 1Article

Systematic review and meta-analysis of the role of somatostatin and its analogues in the treatment of enterocutaneous fistulaSTEVENS, Philip; FOULKES, Rhiannon E; HARTFORD-BEYNON, Jake S et al.European journal of gastroenterology & hepatology. 2011, Vol 23, Num 10, pp 912-922, issn 0954-691X, 11 p.Article

Prise en charge de l'acromégalie évolutive au cours de la grossesse = Management of acromegaly in pregnant womanBEN SALEM HACHMI, L; KAMMOUN, I; BOUZID, C et al.Annales d'endocrinologie. 2010, Vol 71, Num 1, pp 60-63, issn 0003-4266, 4 p.Article

Population Pharmacokinetic Analysis of Lanreotide Autogel® in Healthy Subjects : Evidence for Injection Interval of Up to 2 MonthsTROCONIZ, Inaki F; CENDROS, Josep-Maria; PERAIRE, Concepcion et al.Clinical pharmacokinetics. 2009, Vol 48, Num 1, pp 51-62, issn 0312-5963, 12 p.Article

Lanreotide in Metastatic Enteropancreatic Neuroendocrine TumorsCAPLIN, Martyn E; PAVEL, Marianne; RINDI, Guido et al.The New England journal of medicine. 2014, Vol 371, Num 3, pp 224-233, issn 0028-4793, 10 p.Article

Mésothéliome péritonéal : longue survie sous chimiothérapie intrapéritonéale, lanréotide et mucolytiques = Peritoneal mesothelioma : Long survival with intraperitoneal chemotherapy, lanreotide and mucolyticsMONTMAYEUR, Gaëlle; THIVAT, Emilie; GIMBERGUES, Pierre et al.Gastroentérologie clinique et biologique. 2008, Vol 32, Num 10, pp 874-875, issn 0399-8320, 2 p.Article

The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LARASHWELL, S. G; BEVAN, J. S; EDWARDS, O. M et al.European journal of endocrinology. 2004, Vol 150, Num 4, pp 473-480, issn 0804-4643, 8 p.Article

Dose-dependent gastrointestinal effects of the somatostatin analog lanreotide in healthy volunteersDREWE, J; SIEBER, C. C; MOTTET, C et al.Clinical pharmacology and therapeutics. 1999, Vol 65, Num 4, pp 413-419, issn 0009-9236Article

Chemoprevention of hepatocellular carcinoma. Proof of concept in animal modelsBORBATH, I; STÄRKEL, P.Acta gastro-enterologica belgica (English ed.). 2011, Vol 74, Num 1, pp 34-44, issn 1784-3227, 11 p.Article

Positive octreotide scintigraphy and determination of lanreotide activity in paget's disease of bone associated with phosphate diabetes: a case reportVANDEMERGEL, X; BLOCKLET, D; DECAUX, G et al.Annales d'endocrinologie. 2004, Vol 65, Num 3, pp 201-204, issn 0003-4266, 4 p.Article

Effectiveness and tolerability of 3-year lanreotide Autogel® treatment in patients with acromegalyCARON, Philippe; COGNE, Muriel; RAINGEARD, Isabelle et al.Clinical endocrinology (Oxford. Print). 2006, Vol 64, Num 2, pp 209-214, issn 0300-0664, 6 p.Article

¹¹¹In- and ⁹⁰Y-DOTA-lanreotide: Results and implications of the MAURITIUS trialVIRGOLINI, Irene; BRITTON, Keith; BUSCOMBE, John et al.Seminars in nuclear medicine. 2002, Vol 32, Num 2, pp 148-155, issn 0001-2998Article

Lanreotide treatment of metastatic hepatocellular carcinoma resulting in partial regression and more than 3 years of progression-free survivalBORBATH, Ivan; LHOMMEL, Renaud; GUIOT, Yves et al.Acta gastro-enterologica belgica (English ed.). 2012, Vol 75, Num 2, pp 270-273, issn 1784-3227, 4 p.Article

Does first-line surgery still have its place in the treatment of acromegaly?CASTINETTI, F; MORANGE, I; DUBOIS, N et al.Annales d'endocrinologie. 2009, Vol 70, Num 2, pp 107-112, issn 0003-4266, 6 p.Article

Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors : A phase III studyBAJETTA, Emilio; PROCOPIO, Giuseppe; DE BRAUD, Filippo et al.Cancer. 2006, Vol 107, Num 10, pp 2474-2481, issn 0008-543X, 8 p.Article

Mechanisms of Action and Resistance of Somatostatin Analogues for the Treatment of Hepatocellular Carcinoma : A Message Not Well TakenSAMONAKIS, Dimitrios N; NOTAS, George; CHRISTODOULAKIS, Nikolaos et al.Digestive diseases and sciences. 2008, Vol 53, Num 9, pp 2359-2365, issn 0163-2116, 7 p.Article

Lanreotide Autogel^®: A Review of its Use in the Treatment of Patients with AcromegalyBURNESS, Celeste B; DHILLON, Sohita; KEAM, Susan J et al.Drugs (Basel). 2014, Vol 74, Num 14, pp 1673-1691, issn 0012-6667, 19 p.Article

The long-term outcome of patients with polycystic liver disease treated with lanreotideCHRISPIJN, M; NEVENS, F; DRENTH, J. P. H et al.Alimentary pharmacology & therapeutics. 2012, Vol 35, Num 2, pp 266-274, issn 0269-2813, 9 p.Article

Lanreotide Autogel® : A Review of its Use in the Management of Acromegaly. CommentaryCROXTALL, Jamie D; SCOTT, Lesley J; MOLITCH, Mark E et al.Drugs (Basel). 2008, Vol 68, Num 5, pp 711-724, issn 0012-6667, 14 p.Article

Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotideBORBATH, Ivan; LECLERCQ, Isabelle A; ABARCA-QUINONES, Jorge et al.Cancer science. 2007, Vol 98, Num 12, pp 1831-1839, issn 1347-9032, 9 p.Article

L'acromégalie et ses traitements = Acromegaly and treatmentLa Revue Prescrire. 2004, Vol 24, Num 252, pp 535-537, issn 0247-7750, 3 p.Article

Les agonistes de la somatostatine = Somatostatin agonistesBRUE, T; SAVEANU, A; VALLETTE-KASIC, S et al.MTE. Médecine thérapeutique endocrinologie. 2000, Vol 2, Num 2, pp 137-143, issn 1295-9359Article

Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiencyBARBANOJ, M; ANTONIJOAN, R; OBACH, R et al.Clinical pharmacology and therapeutics. 1999, Vol 66, Num 5, pp 485-491, issn 0009-9236Article